The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG125 – Paclitaxel in combination with pertuzumab and trastuzumab
For the treatment of adults with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease and are considered fit for treatment with pertuzumab plus trastuzumab plus a taxane. (off-label use and off-patent medicine)
- Council meeting date: 11 December 2025
- Planned publication date: 15 January 2026
NCMAG 126 – Nivolumab plus ipilimumab
For use as neoadjuvant treatment of mismatch repair deficient or microsatellite instability‑high locally advanced colon cancer which is judged to be borderline resectable. (off-label use)
- Council meeting date: 19 March 2026
- Planned publication date: 23 April 2026
NCMAG127 - Arsenic trioxide in combination with all-trans retinoic acid
For treatment of adults with high-risk acute promyelocytic leukaemia (APML). (off-label use and off-patent medicine)
- Council meeting date: To be confirmed
- Planned publication date: To be confirmed